News About: Pharm. Industry
Green Cross tops in per capita sales
Green Cross Corp. ranked the highest in per capita sales of 428 million won among 31 listed pharmaceutical companies during a January-September period of this year on the back of robust business performance, according...
Drugmakers stage large-scale rally against government’s drug price reform
Tens of thousands of domestic drug makers staged a mass rally on Nov. 18 to protest what they claim are senseless drug price cuts.
According to the Korean Pharmaceutical Manufacturers Association Friday, about 10,0...
Diabetes drug market in transition
Handok Pharmaceutical’s Amaryl kept its number 1 ranking in local diabetes drug market, but struggles this year against Merck’s Januvia (sitagliptin) which succeeded in overtaking the top position in October.
Januv...
Drug makers to hold rally against massive drug cuts
Korean pharmaceutical companies and related interest groups will stage a mass-scale rally on November 18 to step up their protests against the government’s measure designed to reduce insurance expenditures starting ne...
Listed pharmaceutical firms recruited 1,000 this year
A total of 54 pharmaceutical firms listed on the local KOSPI and KOSDAQ markets hired about 994 new employees between September 2010 and September 2011.
A report released by Yakup.com showed that the number of new ...
Multinational firms seeking to place priority on new drug pricing system
Despite the local pharmaceutical industry’s scheme to hold a large-scale rally tomorrow to protest against the government’s massive drug prices cut plan, multinational firms here decided not to join the rally.
Mult...
Drug makers spend 35.3% of revenue on promotion in 3 quarter
Details of drug company spending in the third quarter of this year revealed recently show that the country's 47 listed pharmaceutical companies on average spend 35.3 percent of their annual revenue on marketing and ho...
KOSPI-listed pharmaceutical firms’ operating profit plunge by 8.9% in third quarter
Korea’s listed pharmaceutical companies saw their third-quarter combined operating profit fall 6.8 percent year-on-year, while net profit dwindle to 14.3%. Sales were up 6.1 percent on average.
The combined net pro...
Januvia, Galvus, Onglyza and Trajenta vie for market share in Korea
Multinational pharmaceutical companies will step up their marketing in the domestic dipeptidyl peptidase-IV (DPP-IV) inhibitors market dominated by Merck’s Januvia (sitagliptin) and Novartis’s Galvus (vildagliptin), w...
M&As looming larger in pharmaceutical industry
The government’s plan to cut domestic drug prices by an average of 14 percent will make it harder for companies to do business in the pharmaceutical market.
Analysts expect a large number of mergers and acquisition...
